IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune’s 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance ...

Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic ... include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally poached its employees and stole trade secrets when developing the ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

The company has discontinued several projects, including noninvasive monitoring of cancer, bilirubin, and diabetes, due to lack of expected progress. Masimo Corp (NASDAQ:MASI) is experiencing ...

Masimo (NASDAQ:MASI ... and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products.

IRVINE, California - Masimo (NASDAQ:MASI) Corporation (NASDAQ:MASI) reported third-quarter earnings that beat analyst expectations, but its shares tumbled 7.5% as fourth-quarter revenue guidance ...

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...